![Mikkel Wandahl Pedersen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mikkel Wandahl Pedersen
No más puestos en curso
Perfil
Mikkel Wandahl Pedersen served as the Chief Scientific Officer at Symphogen A.
He then held the same position at Nykode Therapeutics ASA from 2021 to 2024.
Mr. Pedersen obtained a doctorate degree from the University of Copenhagen.
Antiguos cargos conocidos de Mikkel Wandahl Pedersen.
Empresas | Cargo | Fin |
---|---|---|
NYKODE THERAPEUTICS | Director Técnico/Científico/I+D | 01/06/2024 |
Symphogen A/S
![]() Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Director Técnico/Científico/I+D | - |
Formación de Mikkel Wandahl Pedersen.
University of Copenhagen | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
NYKODE THERAPEUTICS | Health Technology |
Empresas privadas | 1 |
---|---|
Symphogen A/S
![]() Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Health Technology |
- Bolsa de valores
- Insiders
- Mikkel Wandahl Pedersen